Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2008 Apr;69(2):166–179. doi: 10.1016/j.curtheres.2008.04.002

Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients

Ewa Piotrowska 1, Joanna Jakóbkiewicz-Banecka 1,2, Anna Tylki-Szymanska 3, Anna Liberek 4, Agnieszka Maryniak 3, Marcelina Malinowska 1, Barbara Czartoryska 5, Ewa Puk 6, Anna Kloska 1, Tomasz Liberek 7, Sylwia Baranska 1, Alicja Wegrzyn 2, Grzegorz Wegrzyn 1,a
PMCID: PMC3969963  PMID: 24692796

Abstract

Background: Mucopolysaccharidoses (MPSs) are a group of severe metabolic disorders caused by deficiencies in enzymes involved in the degradation of glycosaminoglycans (GAGs)—long chains of sugar carbohydrates in cells that help build bone, cartilage, tendons, corneas, skin, and connective tissue. Although enzyme replacement therapy has become available for the treatment of some types of MPS, effective treatment of neurodegenerative forms of MPS has yet to be determined. Recently, genistein (4',5,7-trihydroxyisoflavone), a specific inhibitor of protein tyrosine kinase, has been found to inhibit GAG synthesis and to reduce GAG concentrations in cultures of fibroblasts of MPS patients. Therefore, a potential substrate reduction therapy has been proposed.

Objective: The aim of this study was to examine urinary GAG concentration, hair morphology, and cognitive function in patients receiving genistin treatment for Sanfilippo syndrome (MPS type III).

Methods:Patients aged 3 to 14 years with a biochemically confirmed diagnosis of MPS IIIA or MPS IIIB were eligible to enroll in this open-label, pilot study. Genistin-rich soy isoflavone extract 5 mg/kg/d was administered PO for 12 months. Urinary GAG concentration, hair morphology,and cognitive function (measured using a modified version of the Brief Assessment Examination [BAE] and parent observations)were measured at baseline and after 12 months of treatment.

Results: Ten patients (6 girls, 4 boys; mean age, 8 years [range,3\2-14 years];mean weight, 28 kg [range, 17\2-43 kg]) were included in the study. All patients had Sanfilippo syndrome; 5 patients had MPS IIIA and 5 had MPS IIIB. After 1 year, statistically significant improvement was found in urinary GAG concentration, hair morphology, and cognitive function. Urinary GAG concentration decreased significantly in all 5 patients with MPS IIIA and in 2 patients with MPS IIIB (P = 0.028). Hair morphology improved significantly in all 5 MPS IIIA patients and in 3 MPS IIIB patients (P = 0.012). A significant increase in the BAE score (by 2-6 points) was noted in 8 patients, while the scores of 2 patients did not change after 12 months of treatment (P = 0.012). No adverse events (AEs) considered related to treatment were reported. Moreover, no AEs not related to the treatment (apart from classical symptoms of MPS III) were noted.

Conclusions: This pilot study found some improvements in GAG concentration, hair morphology, and cognitive function in these pediatric patients with Sanfilippo syndrome treated with genistin-rich soy isoflavone extract for 1 year. Clinical trials are needed to evaluate the efficacy and safety of this potential treatment.

Key words: mucopolysaccharidosis, substrate reduction therapy, genistein, genistin, gene expression

Full Text

The Full Text of this article is available as a PDF (1.5 MB).

References

  • 1.Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; New York, Ny: 2001. pp. 3421–3452. [Google Scholar]
  • 2.Wegrzyn G, Wegrzyn A, Tylki-Szymanska A. A general model for genetic regulation of turn-over of glycosaminoglycans suggests a possible procedure for prediction of severity and clinical progress of mucopolysaccharidoses. Med Hypotheses. 2004;62:986–992. doi: 10.1016/j.mehy.2003.12.027. [DOI] [PubMed] [Google Scholar]
  • 3.Kakkis ED, Muenzer J, Tiller GE. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344:182–188. doi: 10.1056/NEJM200101183440304. [DOI] [PubMed] [Google Scholar]
  • 4.Wraith JE, Clarke LA, Beck M. Enzyme replacement therapy for mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase) J Pediatr. 2004;144:581–588. doi: 10.1016/j.jpeds.2004.01.046. [DOI] [PubMed] [Google Scholar]
  • 5.Sifuentes M, Doroshow R, Hoft R. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007;90:171–180. doi: 10.1016/j.ymgme.2006.08.007. [DOI] [PubMed] [Google Scholar]
  • 6.Muenzer J, Wraith JE, Beck M. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) [published correction appears in Genet Med. 2006;8:599]. Genet Med. 2006;8:465–473. doi: 10.1097/01.gim.0000232477.37660.fb. [DOI] [PubMed] [Google Scholar]
  • 7.Harmatz P, Giugliani R, Schwartz I, for the MPS VI Phase 3 Study Group Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized,double-blind, placebo-controlled,multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148:533–539. doi: 10.1016/j.jpeds.2005.12.014. [DOI] [PubMed] [Google Scholar]
  • 8.Kakkis E, McEntee M, Vogler C. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab. 2004;83:163–174. doi: 10.1016/j.ymgme.2004.07.003. [DOI] [PubMed] [Google Scholar]
  • 9.Dickson P, McEntee M, Vogler C. Intrathecal enzyme replacement therapy: Successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab. 2007;91:61–68. doi: 10.1016/j.ymgme.2006.12.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Schiffmann R, Brady RO. New prospects for the treatment of lysosomal storage diseases. Drugs. 2002;62:733–742. doi: 10.2165/00003495-200262050-00002. [DOI] [PubMed] [Google Scholar]
  • 11.Piotrowska E, Jakóbkiewicz-Banecka J, Baranska S. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet. 2006;14:846–852. doi: 10.1038/sj.ejhg.5201623. [DOI] [PubMed] [Google Scholar]
  • 12.Tirone E, D'Alessandris C, Hascall VC. Hyaluronan synthesis by mouse cumulus cells is regulated by interactions between follicle-stimulating hormone (or epidermal growth factor) and a soluble oocyte factor (or transforming growth factor beta1) J Biol Chem. 1997;272:4787–4794. doi: 10.1074/jbc.272.8.4787. [DOI] [PubMed] [Google Scholar]
  • 13.Pisano MM, Greene RM. Epidermal growth factor potentiates the induction of ornithine decarboxylase activity by prostaglandins in embryonic palate mesenchymal cells: Effects on cell proliferation and glycosaminoglycan synthesis. Dev Biol. 1987;122:419–431. doi: 10.1016/0012-1606(87)90306-x. [DOI] [PubMed] [Google Scholar]
  • 14.Akiyama T, Ishida J, Nakagawa S. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262:5592–5595. [PubMed] [Google Scholar]
  • 15.Kim H, Peterson TG, Barnes S. Mechanisms of action of the soy isoflavone genistein: Emerging role for its effects via transforming growth factor beta signaling pathways. Am J Clin Nutr. 1998;68(Suppl 1):1418S–1425S. doi: 10.1093/ajcn/68.6.1418S. [DOI] [PubMed] [Google Scholar]
  • 16.Tsai TH. Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. J Chromatogr A. 2005;1073:317–322. doi: 10.1016/j.chroma.2004.10.048. [DOI] [PubMed] [Google Scholar]
  • 17.Roberts AL, Thomas BJ, Wilkinson AS. Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr Res. 2006;60:309–314. doi: 10.1203/01.pdr.0000233037.00707.da. [DOI] [PubMed] [Google Scholar]
  • 18.Bloedon LT, Jeffcoat AR, Lopaczynski W. Safety and pharmacokinetics of purified soy isoflavones: Single-dose administration to postmenopausal women. Am J Clin Nutr. 2002;76:112–1137. doi: 10.1093/ajcn/76.5.1126. [DOI] [PubMed] [Google Scholar]
  • 19.McClain RM, Wolz E, Davidovich A. Subchronic and chronic safety studies with genistein in dogs. Food Chem Toxicol. 2005;43:1461–1482. doi: 10.1016/j.fct.2005.02.017. [DOI] [PubMed] [Google Scholar]
  • 20.Ullmann U, Metzner J, Frank T. Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers. Adv Ther. 2005;22:65–78. doi: 10.1007/BF02850186. [DOI] [PubMed] [Google Scholar]
  • 21.Malinowska M, Jakóbkiewicz-Banecka J, Kloska A. Abnormalities in the hair morphology of patients with some but not all types of mucopolysaccharidoses. Eur J Pediatr. 2008;167:203–209. doi: 10.1007/s00431-007-0462-7. [DOI] [PubMed] [Google Scholar]
  • 22.Nester MJ. Use of a brief assessment examination in a study of subacute sclerosing panencephalitis. J Child Neurol. 1996;11:173–180. doi: 10.1177/088307389601100301. [DOI] [PubMed] [Google Scholar]
  • 23.Campbell C, Levin S, Humphreys P. Subacute sclerosing panencephalitis: Results of the Canadian Paediatric Surveillance Program and review of the literature. BMC Pediatr. 2005;5:47. doi: 10.1186/1471-2431-5-47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Kloska A, Bohdanowicz J, Konopa G. Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human alpha-L-iduronidase (laronidase, Aldurazyme) Am J Med Genet A. 2005;139:199–203. doi: 10.1002/ajmg.a.31021. [DOI] [PubMed] [Google Scholar]
  • 25.Tomatsu S, Gutierrez MA, Ishimaru T. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis. 2005;28:743–757. doi: 10.1007/s10545-005-0069-y. [DOI] [PubMed] [Google Scholar]
  • 26.Wegrzyn G, Tylki-Szymanska A, Liberek A. et al. Rapid deterioration of a patient with mucopolysaccharidosis type I during interruption of enzyme replacement therapy. Am J Med Genet. 2007;143:1925–1927. doi: 10.1002/ajmg.a.31831. [DOI] [PubMed] [Google Scholar]
  • 27.Wilcoxon F. Individual comparisons by ranking methods. Biometr Bull. 1945;1:80–83. [Google Scholar]
  • 28.Patterson MC, Vecchio D, Prady H. Miglustat for treatment of Niemann-Pick C disease: A randomised controlled study. Lancet Neurol. 2007;6:765–772. doi: 10.1016/S1474-4422(07)70194-1. [DOI] [PubMed] [Google Scholar]
  • 29.Erickson RP. A first therapy for Niemann-Pick C. Lancet Neurol. 2007;6:748–749. doi: 10.1016/S1474-4422(07)70198-9. [DOI] [PubMed] [Google Scholar]
  • 30.Jakóbkiewicz-Banecka J, Wegrzyn A, Wegrzyn G. Substrate deprivation therapy: A new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases. J Appl Genet. 2007;48:383–388. doi: 10.1007/BF03195237. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES